Literature DB >> 22023089

Predicting the survival of cancer patients recently diagnosed in Sweden and an evaluation of predictions published in 2004.

Mats Talbäck1, Paul W Dickman.   

Abstract

BACKGROUND: Estimates of cancer patient survival from traditional cohort-based methods may be heavily influenced by the survival experience of patients diagnosed many years ago and may not therefore be relevant to recently diagnosed patients. Period-based analysis provides better predictions of survival for recently diagnosed patients than cohort analysis. The first aim of this study is to provide predictions of the long-term survival of patients diagnosed in 2005-2009 using period analysis and to compare these estimates to the latest available cohort estimates. The second aim is to evaluate predictions published in 2004 regarding the future survival of patients diagnosed 2000-2002.
MATERIAL AND METHODS: We studied survival among patients diagnosed 1985-2009 reported to the nationwide, population-based Swedish Cancer Registry. Predictions of the future relative survival for recently diagnosed patients were made using period analysis with a window of 2005-2009.
RESULTS: The predictions made using period analysis and published in 2004 agreed well with the subsequently observed survival, with common sites showing a better agreement than less common sites. Updated predictions suggest that patients diagnosed today can expect improved survival for many forms of cancer.
CONCLUSIONS: Period, rather than cohort, survival analysis should be used if the primary aim is to predict the future survival of recently diagnosed patients. Recently diagnosed cancer patients can, for many forms of cancer, expect an improved survival compared to patients diagnosed only a few years earlier.

Entities:  

Mesh:

Year:  2011        PMID: 22023089     DOI: 10.3109/0284186X.2011.626444

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  6 in total

1.  Survival after a diagnosis of testicular germ cell cancers in Germany and the United States, 2002-2006: a high resolution study by histology and age.

Authors:  A Stang; L Jansen; B Trabert; C Rusner; A Eberle; A Katalinic; K Emrich; B Holleczek; H Brenner
Journal:  Cancer Epidemiol       Date:  2013-04-23       Impact factor: 2.984

2.  Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data.

Authors:  Yuri Ito; Isao Miyashiro; Hidemi Ito; Satoyo Hosono; Dai Chihara; Kayo Nakata-Yamada; Masashi Nakayama; Masashi Matsuzaka; Masakazu Hattori; Hiromi Sugiyama; Isao Oze; Rina Tanaka; Etsuko Nomura; Yoshikazu Nishino; Tomohiro Matsuda; Akiko Ioka; Hideaki Tsukuma; Tomio Nakayama
Journal:  Cancer Sci       Date:  2014-10-18       Impact factor: 6.716

3.  Types of second primary cancers influence survival in chronic lymphocytic and hairy cell leukemia patients.

Authors:  Guoqiao Zheng; Subhayan Chattopadhyay; Amit Sud; Kristina Sundquist; Jan Sundquist; Asta Försti; Richard S Houlston; Akseli Hemminki; Kari Hemminki
Journal:  Blood Cancer J       Date:  2019-03-26       Impact factor: 11.037

4.  Illustration of different modelling assumptions for estimation of loss in expectation of life due to cancer.

Authors:  Therese M-L Andersson; Mark J Rutherford; Paul C Lambert
Journal:  BMC Med Res Methodol       Date:  2019-07-09       Impact factor: 4.615

5.  Recent Improvement in the Long-term Survival of Breast Cancer Patients by Age and Stage in Japan.

Authors:  Akiyo Yoshimura; Hidemi Ito; Yoshikazu Nishino; Masakazu Hattori; Tomohiro Matsuda; Isao Miyashiro; Tomio Nakayama; Hiroji Iwata; Keitaro Matsuo; Hideo Tanaka; Yuri Ito
Journal:  J Epidemiol       Date:  2018-02-24       Impact factor: 3.211

6.  Second Primary Cancers in Melanoma Patients Critically Shorten Survival.

Authors:  Guoqiao Zheng; Subhayan Chattopadhyay; Kristina Sundquist; Jan Sundquist; Asta Försti; Akseli Hemminki; Kari Hemminki
Journal:  Clin Epidemiol       Date:  2020-01-23       Impact factor: 4.790

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.